Curat Global LLC bought a new position in CVS Health Co. (NYSE:CVS - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 11,560 shares of the pharmacy operator's stock, valued at approximately $783,000.
Other institutional investors have also made changes to their positions in the company. Generali Investments Management Co LLC acquired a new position in shares of CVS Health in the first quarter worth $337,000. Riverview Trust Co raised its position in CVS Health by 119.3% in the first quarter. Riverview Trust Co now owns 956 shares of the pharmacy operator's stock worth $65,000 after purchasing an additional 520 shares in the last quarter. Vest Financial LLC increased its position in shares of CVS Health by 73.5% during the 1st quarter. Vest Financial LLC now owns 16,707 shares of the pharmacy operator's stock worth $1,132,000 after purchasing an additional 7,077 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. increased its position in shares of CVS Health by 19.3% during the 1st quarter. Thurston Springer Miller Herd & Titak Inc. now owns 10,858 shares of the pharmacy operator's stock worth $736,000 after purchasing an additional 1,757 shares in the last quarter. Finally, Apella Capital LLC acquired a new stake in shares of CVS Health during the 1st quarter worth about $269,000. 80.66% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In related news, Director Guy P. Sansone purchased 1,570 shares of CVS Health stock in a transaction dated Thursday, June 5th. The shares were bought at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the purchase, the director now owns 12,007 shares in the company, valued at approximately $764,845.90. This trade represents a 15.04% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.22% of the stock is currently owned by corporate insiders.
CVS Health Price Performance
Shares of CVS Health stock traded up $0.29 on Monday, reaching $63.87. 3,683,106 shares of the stock were exchanged, compared to its average volume of 11,055,991. The firm's 50 day moving average is $65.21 and its 200-day moving average is $59.94. CVS Health Co. has a one year low of $43.56 and a one year high of $72.51. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The firm has a market cap of $80.80 billion, a PE ratio of 17.45, a P/E/G ratio of 0.98 and a beta of 0.56.
CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.63. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The company had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. During the same quarter in the prior year, the firm posted $1.31 EPS. The firm's quarterly revenue was up 7.0% on a year-over-year basis. As a group, analysts anticipate that CVS Health Co. will post 5.89 EPS for the current fiscal year.
CVS Health Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were paid a $0.665 dividend. The ex-dividend date of this dividend was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.16%. CVS Health's payout ratio is currently 63.48%.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on the stock. Robert W. Baird increased their price target on shares of CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a research note on Tuesday, April 15th. Wall Street Zen raised shares of CVS Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Argus set a $77.00 price target on shares of CVS Health in a research note on Tuesday, February 18th. Leerink Partners raised shares of CVS Health from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $55.00 to $75.00 in a research note on Thursday, February 13th. Finally, Morgan Stanley reiterated an "overweight" rating on shares of CVS Health in a research note on Tuesday, April 15th. Two investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, CVS Health currently has a consensus rating of "Moderate Buy" and a consensus target price of $74.75.
Read Our Latest Report on CVS
About CVS Health
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Articles
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
